Thursday, December 9, 2021, San Antonio, TX, 7:00 PM – 8:45 PM Central Time (8:00 PM – 9:45 PM Eastern Time)

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Triple-Negative Breast Cancer (Part 3 of a 3-Part Series)

A CME Satellite Symposium Held in Conjunction with SABCS®2021

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:45 PM — Educational Meeting

Meeting Room
Grand Ballroom G-M (3rd floor)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in San Antonio, TX, preregistration is required as seating is limited.  
 
Faculty
Adam M Brufsky, MD, PhD
Professor of Medicine
Co-Director, Comprehensive Breast Cancer Center
UPMC Hillman Cancer Center
Associate Division Chief, Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh
Pittsburgh, Pennsylvania

Rita Nanda, MD
Director, Breast Oncology
Associate Professor of Medicine
Section of Hematology/Oncology
The University of Chicago
Chicago, Illinois


Melinda Telli, MD
Associate Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Stanford, California

Moderator
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc and Merck.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 8:45 PM — Educational Meeting

MODULE 1: Promising Therapeutic Strategies for Patients with Localized Triple-Negative Breast Cancer (TNBC)

MODULE 2: Optimal Integration of Immune Checkpoint Inhibitors into the Management of Metastatic TNBC (mTNBC)

MODULE 3: Current and Future Role of PARP Inhibitors for Patients with mTNBC

MODULE 4: Other Novel Treatment Options and Investigational Strategies for TNBC

Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Review available research data supporting the use of chemotherapy in combination with anti-PD-1/PD-L1 antibodies for newly diagnosed PD-L1-positive triple-negative breast cancer (TNBC), and use this information to identify patients who may be appropriate for this approach.
  • Evaluate published research findings, clinical factors (eg, age, performance status, prior therapeutic exposure) and patient preferences in the selection and sequencing of available therapeutic agents for patients with PD-L1-negative TNBC or those who experience disease progression on front-line chemoimmunotherapy.
  • Consider available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies for patients with localized TNBC, and reflect on the potential role of these strategies in clinical practice.
  • Assess the mechanism of action of and available research findings with the use of plinabulin in combination with pegfilgrastim in the prevention of chemotherapy-related neutropenia, and examine the potential future role of this strategy for patients with BC.
  • Appraise published efficacy and safety data with PARP inhibitors for patients with metastatic BC harboring BRCA1/2 mutations, and consider the diagnostic and therapeutic implications for nonresearch care.
  • Appreciate emerging Phase III data documenting the efficacy of olaparib as adjuvant therapy for patients with BRCA-mutated high-risk HER2-negative localized BC, and consider the potential future role of this strategy in clinical practice.
  • Recall the design of ongoing clinical trials evaluating other investigational PARP inhibitors and novel applications of PARP inhibitors alone or in combination with other systemic approaches (eg, immunotherapy, chemotherapy) for BC, and counsel appropriate patients about availability and participation.
  • Understand the FDA-approved indication for sacituzumab govitecan, and optimally incorporate this novel therapy into current treatment algorithms for patients with relapsed/refractory TNBC.
  • Analyze the mechanisms of action of, early data with and ongoing clinical trials evaluating other novel agents and treatment strategies under development for TNBC.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Brufsky Consulting Agreements: Agendia Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Myriad Genetic Laboratories Inc, Novartis, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc, Spectrum Pharmaceuticals Inc. Dr NandaAdvisory Committee: Cardinal Health, Clovis Oncology, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, iTeos Therapeutics, MacroGenics Inc, Merck, OncoSec Medical, Pfizer Inc, Seagen Inc; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Corcept Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Merck, OBI Pharma Inc, Odonate Therapeutics, OncoSec Medical, Pfizer Inc, Seagen Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: G1 Therapeutics Inc. Dr TelliAdvisory Committee: AbbVie Inc, Aduro Biotech, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Celgene Corporation, Daiichi Sankyo Inc, G1 Therapeutics Inc, Immunomedics Inc, Lilly, Natera Inc, Novartis, OncoSec Medical, Pfizer Inc, Sanofi Genzyme; Consulting Agreements: Genentech, a member of the Roche Group, Guardant Health, Merck; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biothera Pharmaceuticals Inc, Calithera Biosciences, EMD Serono Inc, Genentech, a member of the Roche Group, Merck, OncoSec Medical, Pfizer Inc, PharmaMar, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: G1 Therapeutics Inc, Immunomedics Inc.

MODERATORHope S Rugo, MDConsulting Agreement: Samsung Bioepis (limited consulting); Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, MacroGenics Inc, Merck, Novartis, OBI Pharma Inc, Odonate Therapeutics, Pfizer Inc, Seagen Inc, Sermonix Pharmaceuticals; Honoraria: Mylan, Puma Biotechnology Inc; Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, MacroGenics Inc, Merck, Mylan, Novartis, Pfizer Inc.

SLIDES CONTRIBUTOR - Professor Peter Schmid, FRCP, MD, PhDConsulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc; Spouse Employment/Salary: Roche Laboratories Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Gilead Sciences Inc and Merck.

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (3rd floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center.

 
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

There is no fee to participate in this program or live webcast of this event.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live broadcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.